

## END USER RIGHTS Premade LentiFlash® for gene editing

### [1] Flash Therapeutics' technology

Flash Therapeutics' highly concentrated and purified lentiviral vectors and its use are covered by U.S. Patent No. 13/0029379 and WO 2013/014537. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Academic and not-for-profit research institutions whose research using the Flash Therapeutics' Technology or the product obtained by the Flash Therapeutics' technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from Flash Therapeutics in order to use the Flash Therapeutics' Technology or the product obtained by the Flash Therapeutics' technology. Please contact Flash Therapeutics for information on purchasing a license to use these products for commercial purposes: 3 Avenue Hubert Curien, Centre d'Innovation Langlade, 31100 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: [sandy.darrigan@flashtherapeutics.com](mailto:sandy.darrigan@flashtherapeutics.com)

### [7] LentiFlash technology

#### 1 Definitions

**"FLASH THERAPEUTICS Affiliates"** shall mean any company, organization, or any other entity, which is, in fact or at law, directly or indirectly, controlled by FLASH THERAPEUTICS or controlled by an entity within a group of companies of which VECTALY is a member, or "controls" FLASH THERAPEUTICS ("control" refers to the holding of the majority of the voting rights in the general meetings).

**"Commercial"** shall mean the sale of products using LentiFlash® Technology, services using LentiFlash® Technology, information, or data, the resale LentiFlash® Technology, whether or not such LentiFlash® Technology is resold for research purposes.

**"Confidential Information"** shall mean all information related to LentiFlash® Technology, in particular the plasmids' sequences, and any Improvements of the Particle and Combined Improvements, as well as informations related to the sequence of interest provided by the Purchaser.

**"Improvements of the Particle"** shall mean:

- any new qualitative and quantitative properties, or any new ability or characteristics of the Particle, independently of the transferred sequence of interest,
- any new technique, know-how, any new means or process using the Particle, independently of the transferred sequence of interest,
- any new method of use of the Particle, independently of the transferred sequence of interest.

**"Combined Improvements"** shall mean all new product or reagent obtained by the use of Products, all new technique or know-how using the Products and all new mean or process, patentable or not, from the use of LentiFlash® Technology by the Purchaser, or all new method of use of LentiFlash® Technology.

**"Products"** shall means viral particles for RNA transfer covered by LentiFlash® Technology and the sequence of interest to be transferred in target cells.

**"Results"** shall mean all technique, method, process, know-how, material, biological material, test, development, discovery, invention, product, program, research, and any means or process, whether or not patentable, developed or generated by the Purchaser, particularly discovery of new molecules and gene functionality study, to the exclusion of any Improvement of the Particle and Combined Improvement.

“**Services**” shall mean cellular and tissue engineering services including the use of Products, and the corresponding analysis.

“**LentiFlash® Technology**” shall mean all element covered by the French pending patent application FR1554381 and the PCT application WO2016185125, the French pending patent application FR1654332 and the PCT application WO2017194902, the French pending patent application FR1654333 and the PCT application WO2017194903, their components, materials made using these particles or its components, Derivatives and the sequence information provided with these particles.

“**Therapeutic**” shall mean therapeutic applications of which the gene therapy, the genome editing and the immunotherapy.

## **2 Scope**

The End User Rights LENTIFLASH® defines the rights of use Products and Services provided by FLASH THERAPEUTICS to the Purchaser. All other FLASH THERAPEUTICS products are subject to FLASH THERAPEUTICS’ general end user rights document.

## **3 Limited transfer rights**

FLASH THERAPEUTICS’s products or services are sold or provided to the Purchaser in compensation for the payment of the agreed purchase price.

Within the same sale and purchase agreement and without any additional charges, the Purchaser shall also be transferred the right to use ® Technology through a limited, royalty free, non exclusive and non transferable license for internal research purposes to the exclusion of any Commercial Purposes or Therapeutic purposes.

However, should the Purchaser be interested in using LentiFlash® Technology for Commercial purposes or Therapeutic purposes, it will have to notify its interest to FLASH THERAPEUTICS in writing so that a license agreement shall be negotiated.

## **4 Property of the Results**

The Results generated by the Purchaser are the exclusive property of the Purchaser.

## **5 Improvements of the LentiFlash® Technology**

As soon as the Purchaser considers that an Improvement may be likely to protection and exploitation through any intellectual or industrial property rights or to any kind of communication or publication, it shall previously notify in writing FLASH THERAPEUTICS.

### **5.1 Improvements of the Particle**

Any Improvement of the Particle obtained by the Purchaser shall belong exclusively to FLASH THERAPEUTICS.

### **5.2 Combined Improvements**

In case the Purchaser obtains Combined Improvements, the Parties shall discuss and negotiate to make a determination as to whom the property shall belong or as to how it shall be shared. The Parties shall also negotiate the way the Combined Improvements shall be used for Commercial Purposes or Therapeutic Purposes. The Purchaser shall not apply for a patent or try to protect the property of such a Combined Improvement until the Parties have reached an agreement.

## **6 Publications and communications**

The Purchaser is free to publish or communicate its Results.

All written or oral publications and communications relating to the use of LentiFlash® Technology shall refer to the fact that the LentiFlash® Technology is proprietary to FLASH THERAPEUTICS, by incorporating the following sentence:

*“We used LentiFlash® Technology from FLASH THERAPEUTICS SAS, Toulouse (France), covered by European patent EP1974043 (B1) licensed by Oxford Biomedica to FLASH THERAPEUTICS and PCT pending patent application WO2016185125 owned by FLASH THERAPEUTICS”.*

All written or oral publications and communications that contain or mention Improvements of the Particles or Combined Improvements pertaining to the use of the LentiFlash® Technology are subject to FLASH THERAPEUTICS' prior written approval. FLASH THERAPEUTICS' right of refusal shall be notified in writing to the Purchaser within two (2) weeks from the receipt of the information provided by the Purchaser.

## **7 Confidentiality**

The Parties shall keep confidential all Confidential Information transmitted by the other Partie according to the present End User Rights LentiFlash®. Confidential Information shall not be disclosed to third parties without the disclosing Party's prior written authorization.

This non-disclosure obligation shall not apply to Confidential Information which the receiving Party is likely to demonstrate by documentary evidence that it:

- (a) was in its possession prior to being provided by the disclosing Party, as evidenced by its written records; or
- (b) was publicly available at the time of receipt from the disclosing Party; or
- (c) became part of the public domain through no fault of the receiving Party, its directors, officers or employees; or
- (d) was known to the receiving Party without breaching any confidentiality obligation; or
- (e) was independently developed by the receiving Party as evidenced by its written records; or
- (f) is required by law, regulation, rule, act, or order of any governmental authority or agency to be disclosed by the receiving Party; provided, however, that the receiving Party gives sufficient advance written notice to permit the disclosing Party to seek a protective order or other similar order with respect to such Confidential Information and thereafter discloses only the minimum Confidential Information required to be disclosed in order to comply.

This non-disclosure obligation shall remain effective for five (5) years subsequent to the transfer of LentiFlash® Technology.

## **8 Warranty**

FLASH THERAPEUTICS makes no warranties, express or implied of any kind and hereby disclaims any warranties, representations or guarantees of any kind whatsoever with respect to LentiFlash® Technology, any patents, products related thereto and/or information provided under this agreement, including without limitation, accuracy, completeness, performance, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement of third party patents, copyright, trade secret, trademark or other proprietary rights.

## **9 Liabilities**

Both FLASH THERAPEUTICS and the Purchaser agree to be solely responsible for their own respective liabilities, demands, damages, expenses, attorney's fees, and losses arising out of the use of LentiFlash® Technology. However, the Purchaser shall indemnify FLASH THERAPEUTICS from and against any claims



v20180516

or losses due to the gross negligence or intentional misconduct of the Purchaser in the use of LentiFlash® Technology.